Eiger BioPharmaceuticals, Inc. (EIGR): Price and Financial Metrics

Eiger BioPharmaceuticals, Inc. (EIGR): $1.65

0.23 (+16.20%)

POWR Rating

Component Grades













Add EIGR to Watchlist
Sign Up

Industry: Biotech



in industry


  • EIGR scores best on the Sentiment dimension, with a Sentiment rank ahead of 70.07% of US stocks.
  • The strongest trend for EIGR is in Value, which has been heading up over the past 177 days.
  • EIGR's current lowest rank is in the Stability metric (where it is better than 3.3% of US stocks).

EIGR Stock Summary

  • Over the past twelve months, EIGR has reported earnings growth of 227.58%, putting it ahead of 92.98% of US stocks in our set.
  • The volatility of EIGER BIOPHARMACEUTICALS INC's share price is greater than that of 92.63% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EIGR comes in at -129.81% -- higher than that of merely 4.47% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EIGER BIOPHARMACEUTICALS INC are HUMA, IKNA, GSIT, SURF, and SQZ.
  • EIGR's SEC filings can be seen here. And to visit EIGER BIOPHARMACEUTICALS INC's official web site, go to www.eigerbio.com.

EIGR Valuation Summary

  • In comparison to the median Healthcare stock, EIGR's price/sales ratio is 13.73% lower, now standing at 4.4.
  • EIGR's EV/EBIT ratio has moved up 5.8 over the prior 109 months.

Below are key valuation metrics over time for EIGR.

Stock Date P/S P/B P/E EV/EBIT
EIGR 2023-01-20 4.4 0.8 -0.7 -0.8
EIGR 2023-01-19 4.2 0.8 -0.6 -0.8
EIGR 2023-01-18 4.2 0.8 -0.6 -0.8
EIGR 2023-01-17 4.6 0.8 -0.7 -0.9
EIGR 2023-01-13 4.7 0.8 -0.7 -0.9
EIGR 2023-01-12 4.3 0.8 -0.7 -0.8

EIGR Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 56.59%.
  • The 3 year cash and equivalents growth rate now stands at -26.57%.
  • The 2 year net cashflow from operations growth rate now stands at -19.84%.
Over the past 33 months, EIGR's revenue has gone up $14,148,000.

The table below shows EIGR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 14.148 -77.528 -93.406
2022-06-30 13.163 -76.228 -88.518
2022-03-31 11.169 -74.868 -85.808
2021-12-31 12.142 -71.342 -33.917
2021-09-30 8.782 -70.092 -30.955
2021-06-30 5.743 -64.94 -24.412

EIGR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EIGR has a Quality Grade of F, ranking ahead of 1.43% of graded US stocks.
  • EIGR's asset turnover comes in at 0.037 -- ranking 341st of 682 Pharmaceutical Products stocks.
  • ATNM, MNOV, and ATRA are the stocks whose asset turnover ratios are most correlated with EIGR.

The table below shows EIGR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.037 0.944 -0.198
2021-03-31 0.026 0.985 -0.184
2020-12-31 0.000 NA -0.662
2020-09-30 0.000 NA -0.741
2020-06-30 0.000 NA -0.740
2020-03-31 0.000 NA -0.691

EIGR Price Target

For more insight on analysts targets of EIGR, see our EIGR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.33 Average Broker Recommendation 1 (Strong Buy)

EIGR Stock Price Chart Interactive Chart >

Price chart for EIGR

EIGR Price/Volume Stats

Current price $1.65 52-week high $10.02
Prev. close $1.42 52-week low $0.96
Day low $1.42 Volume 1,375,900
Day high $1.76 Avg. volume 622,684
50-day MA $2.16 Dividend yield N/A
200-day MA $5.76 Market Cap 72.72M

Eiger BioPharmaceuticals, Inc. (EIGR) Company Bio

Eiger BioPharmaceutical Inc, formerly Celladon Corporation, is a clinical-stage biotechnology company engaged in the development of cardiovascular gene therapy. The company was founded in 2008 and is based in Palo Alto, California.

EIGR Latest News Stream

Event/Time News Detail
Loading, please wait...

EIGR Latest Social Stream

Loading social stream, please wait...

View Full EIGR Social Stream

Latest EIGR News From Around the Web

Below are the latest news stories about EIGER BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate EIGR as an investment opportunity.

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

Yahoo | January 18, 2023

The Scientific Founder & Independent Director of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Jeffrey Glenn, Just Bought 43% More Shares

Potential Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders may wish to note that the Scientific Founder...

Yahoo | December 29, 2022

Newsflash: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Have Been Trimming Their Revenue Forecasts

One thing we could say about the analysts on Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) - they aren't optimistic...

Yahoo | December 20, 2022

Eiger BioPharmaceuticals Announces Leadership Change

PALO ALTO, Calif., December 15, 2022--Eiger BioPharmaceuticals, Inc. ("Eiger" or "the company") (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, and its Board of Directors today announced that David A. Cory has resigned as President, Chief Executive Officer and member of the Board of Directors, effective immediately.

Yahoo | December 15, 2022

Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced topline primary Week 48 data from its landmark Phase 3 D-LIVR study (N=407) evaluating lonafarnib, a first-in-class prenylation inhibitor, in two regimens in patients with chronic HDV: lonafarnib boosted with ritonavir alone (all-oral) and in combination with peginterferon alfa (c

Yahoo | December 8, 2022

Read More 'EIGR' Stories Here

EIGR Price Returns

1-mo 39.83%
3-mo -65.77%
6-mo -82.90%
1-year -61.81%
3-year -86.65%
5-year -80.59%
YTD 39.83%
2022 -77.26%
2021 -57.77%
2020 -17.52%
2019 46.65%
2018 -27.17%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8732 seconds.